MEF2C and Alzheimer disease: Notably, our qPCR results demonstrated that BM-MSCs respond more effectively to the combined treatment protocol compared with AD-MSCs, as evidenced by significantly higher expression levels of MEF2c and Troponin I in the BM-MSC groups treated with both 5-Azacytidine and growth factors, compared with treatment with 5-Azacytidine alone.